Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
194M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
121M
-
Shares change
-
+2.52M
-
Total reported value, excl. options
-
$8.58B
-
Value change
-
+$180M
-
Put/Call ratio
-
0.35
-
Number of buys
-
99
-
Number of sells
-
-44
-
Price
-
$71.11
Significant Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q4 2020
184 filings reported holding BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 121M shares
of 194M outstanding shares and own 62.28% of the company stock.
Largest 10 shareholders include Kohlberg Kravis Roberts & Co. L.P. (34.5M shares), VIKING GLOBAL INVESTORS LP (26.6M shares), PERCEPTIVE ADVISORS LLC (6.71M shares), BlackRock Inc. (6.52M shares), VANGUARD GROUP INC (6.44M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (4.71M shares), Aisling Capital Management LP (3.99M shares), AMERICAN INTERNATIONAL GROUP, INC. (3.34M shares), SC US (TTGP), LTD. (2.54M shares), and STATE STREET CORP (2.3M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.